Literature DB >> 22218863

Investigation of membrane protein interactions using the split-ubiquitin membrane yeast two-hybrid system.

Julia Petschnigg1, Victoria Wong, Jamie Snider, Igor Stagljar.   

Abstract

Proteins are generally organized into molecular complexes, in which multiple interaction partners collaborate to carry out cellular processes. Thus, techniques to map protein-protein interactions have become pivotal for biological studies of as yet uncharacterized proteins. Investigation of interaction partners of membrane proteins is of special interest, as they play a major role in cellular processes and are often directly linked to human diseases. Owing to their hydrophobic nature, however, it has proven difficult to study their interaction partners. To circumvent this problem, a yeast-based genetic technology for the in vivo detection of membrane protein interactions, the split-ubiquitin membrane yeast two-hybrid (MYTH) system, has been developed. MYTH allows for detection of both stable and transient interactions and can be applied to large- and small-scale screens. It uses the split-ubiquitin approach, in which the reconstitution of two ubiquitin halves is mediated by a specific protein-protein interaction. Briefly, the bait membrane protein is fused to the C-terminal half of ubiquitin and an artificial transcription factor. The mutated N-terminal moiety of ubiquitin is fused to the prey protein. Upon interaction of bait and prey proteins, ubiquitin is reconstituted and further recognized by ubiquitin-specific proteases, which subsequently cleave off the transcription factor, thus resulting in reporter gene activation. To date, MYTH has been successfully applied to study interactions of membrane proteins from various organisms and has only recently been adapted for the identification of interaction partners of mammalian receptor tyrosine kinases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22218863     DOI: 10.1007/978-1-61779-455-1_13

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  7 in total

1.  Identification of novel ATP13A2 interactors and their role in α-synuclein misfolding and toxicity.

Authors:  Marija Usenovic; Adam L Knight; Arpita Ray; Victoria Wong; Kevin R Brown; Guy A Caldwell; Kim A Caldwell; Igor Stagljar; Dimitri Krainc
Journal:  Hum Mol Genet       Date:  2012-05-29       Impact factor: 6.150

2.  Ligand-based receptor identification on living cells and tissues using TRICEPS.

Authors:  Andreas P Frei; Hansjoerg Moest; Karel Novy; Bernd Wollscheid
Journal:  Nat Protoc       Date:  2013-06-13       Impact factor: 13.491

Review 3.  Multi-functionality of proteins involved in GPCR and G protein signaling: making sense of structure-function continuum with intrinsic disorder-based proteoforms.

Authors:  Alexander V Fonin; April L Darling; Irina M Kuznetsova; Konstantin K Turoverov; Vladimir N Uversky
Journal:  Cell Mol Life Sci       Date:  2019-08-19       Impact factor: 9.261

Review 4.  Fundamentals of protein interaction network mapping.

Authors:  Jamie Snider; Max Kotlyar; Punit Saraon; Zhong Yao; Igor Jurisica; Igor Stagljar
Journal:  Mol Syst Biol       Date:  2015-12-17       Impact factor: 11.429

5.  Molecular Evidence of Adenosine Deaminase Linking Adenosine A2A Receptor and CD26 Proteins.

Authors:  Estefanía Moreno; Júlia Canet; Eduard Gracia; Carme Lluís; Josefa Mallol; Enric I Canela; Antoni Cortés; Vicent Casadó
Journal:  Front Pharmacol       Date:  2018-02-15       Impact factor: 5.810

6.  MOR is not enough: identification of novel mu-opioid receptor interacting proteins using traditional and modified membrane yeast two-hybrid screens.

Authors:  Jessica Petko; Stephanie Justice-Bitner; Jay Jin; Victoria Wong; Saranya Kittanakom; Thomas N Ferraro; Igor Stagljar; Robert Levenson
Journal:  PLoS One       Date:  2013-06-28       Impact factor: 3.240

Review 7.  How to prove the existence of metabolons?

Authors:  Jean-Etienne Bassard; Barbara Ann Halkier
Journal:  Phytochem Rev       Date:  2017-04-26       Impact factor: 5.374

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.